Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.
Identifieur interne : 002F23 ( Ncbi/Checkpoint ); précédent : 002F22; suivant : 002F24Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.
Auteurs : Anne Marthe Meppelink [Pays-Bas] ; Rickard Nyman ; Teus Van Laar ; Martje Drent ; Ted Prins ; Klaus Leonhard LeendersSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2011.
English descriptors
- KwdEn :
- Administration, Cutaneous, Adult, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Carbidopa (administration & dosage), Carbidopa (therapeutic use), Drug Combinations, Duodenum, Female, Humans, Levodopa (administration & dosage), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Patient Satisfaction, Quality of Life, Severity of Illness Index, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Carbidopa, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Levodopa.
- drug therapy : Parkinson Disease.
- Administration, Cutaneous, Adult, Aged, Drug Combinations, Duodenum, Female, Humans, Male, Middle Aged, Patient Satisfaction, Quality of Life, Severity of Illness Index, Treatment Outcome.
Abstract
Motor fluctuations in Parkinson's disease (PD) can be reduced by intraduodenal infusion of levodopa-carbidopa (Duodopa®) via percutaneous endoscopic gastrojejunostomy (PEG). We applied the transcutaneous soft-tissue anchored titanium port (T-port) in 15 PD patients with motor fluctuations; 7 Duodopa-naive (non-PEG), and 8 previously receiving Duodopa (former-PEG). Motor scores (UPDRS-III) and quality of life (QOL, PDQ-8) were assessed at baseline and 6 month follow-up. Six patients had local irritation shortly after implantation, persisting in one patient at 6 month follow-up, which led to explantation. After having finished the protocol, four T-ports were explanted in total. UPDRS-III and PDQ-8 scores improved moderately in the non-PEG patients, but remained similar in the former-PEG users. Two former-PEG users developed polyneuropathy. No obstructions, retractions, or leakages occurred. Technical and hygienic properties of the T-port were preferred by most patients. The T-port seems to be suitable for most PD patients qualifying for Duodopa therapy, although local infection may lead to explantation during longer-term follow-up.
DOI: 10.1002/mds.23408
PubMed: 20960486
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001494
- to stream PubMed, to step Curation: 001494
- to stream PubMed, to step Checkpoint: 001018
- to stream Ncbi, to step Merge: 002F23
- to stream Ncbi, to step Curation: 002F23
Links to Exploration step
pubmed:20960486Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.</title><author><name sortKey="Meppelink, Anne Marthe" sort="Meppelink, Anne Marthe" uniqKey="Meppelink A" first="Anne Marthe" last="Meppelink">Anne Marthe Meppelink</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Medical Center Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Nyman, Rickard" sort="Nyman, Rickard" uniqKey="Nyman R" first="Rickard" last="Nyman">Rickard Nyman</name></author><author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name></author><author><name sortKey="Drent, Martje" sort="Drent, Martje" uniqKey="Drent M" first="Martje" last="Drent">Martje Drent</name></author><author><name sortKey="Prins, Ted" sort="Prins, Ted" uniqKey="Prins T" first="Ted" last="Prins">Ted Prins</name></author><author><name sortKey="Leenders, Klaus Leonhard" sort="Leenders, Klaus Leonhard" uniqKey="Leenders K" first="Klaus Leonhard" last="Leenders">Klaus Leonhard Leenders</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="doi">10.1002/mds.23408</idno><idno type="RBID">pubmed:20960486</idno><idno type="pmid">20960486</idno><idno type="wicri:Area/PubMed/Corpus">001494</idno><idno type="wicri:Area/PubMed/Curation">001494</idno><idno type="wicri:Area/PubMed/Checkpoint">001018</idno><idno type="wicri:Area/Ncbi/Merge">002F23</idno><idno type="wicri:Area/Ncbi/Curation">002F23</idno><idno type="wicri:Area/Ncbi/Checkpoint">002F23</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.</title><author><name sortKey="Meppelink, Anne Marthe" sort="Meppelink, Anne Marthe" uniqKey="Meppelink A" first="Anne Marthe" last="Meppelink">Anne Marthe Meppelink</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Medical Center Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Nyman, Rickard" sort="Nyman, Rickard" uniqKey="Nyman R" first="Rickard" last="Nyman">Rickard Nyman</name></author><author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name></author><author><name sortKey="Drent, Martje" sort="Drent, Martje" uniqKey="Drent M" first="Martje" last="Drent">Martje Drent</name></author><author><name sortKey="Prins, Ted" sort="Prins, Ted" uniqKey="Prins T" first="Ted" last="Prins">Ted Prins</name></author><author><name sortKey="Leenders, Klaus Leonhard" sort="Leenders, Klaus Leonhard" uniqKey="Leenders K" first="Klaus Leonhard" last="Leenders">Klaus Leonhard Leenders</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (therapeutic use)</term><term>Drug Combinations</term><term>Duodenum</term><term>Female</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Patient Satisfaction</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Adult</term><term>Aged</term><term>Drug Combinations</term><term>Duodenum</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Patient Satisfaction</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Motor fluctuations in Parkinson's disease (PD) can be reduced by intraduodenal infusion of levodopa-carbidopa (Duodopa®) via percutaneous endoscopic gastrojejunostomy (PEG). We applied the transcutaneous soft-tissue anchored titanium port (T-port) in 15 PD patients with motor fluctuations; 7 Duodopa-naive (non-PEG), and 8 previously receiving Duodopa (former-PEG). Motor scores (UPDRS-III) and quality of life (QOL, PDQ-8) were assessed at baseline and 6 month follow-up. Six patients had local irritation shortly after implantation, persisting in one patient at 6 month follow-up, which led to explantation. After having finished the protocol, four T-ports were explanted in total. UPDRS-III and PDQ-8 scores improved moderately in the non-PEG patients, but remained similar in the former-PEG users. Two former-PEG users developed polyneuropathy. No obstructions, retractions, or leakages occurred. Technical and hygienic properties of the T-port were preferred by most patients. The T-port seems to be suitable for most PD patients qualifying for Duodopa therapy, although local infection may lead to explantation during longer-term follow-up.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country><region><li>Groningue (province)</li></region><settlement><li>Groningue</li></settlement></list><tree><noCountry><name sortKey="Drent, Martje" sort="Drent, Martje" uniqKey="Drent M" first="Martje" last="Drent">Martje Drent</name><name sortKey="Leenders, Klaus Leonhard" sort="Leenders, Klaus Leonhard" uniqKey="Leenders K" first="Klaus Leonhard" last="Leenders">Klaus Leonhard Leenders</name><name sortKey="Nyman, Rickard" sort="Nyman, Rickard" uniqKey="Nyman R" first="Rickard" last="Nyman">Rickard Nyman</name><name sortKey="Prins, Ted" sort="Prins, Ted" uniqKey="Prins T" first="Ted" last="Prins">Ted Prins</name><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name></noCountry><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Meppelink, Anne Marthe" sort="Meppelink, Anne Marthe" uniqKey="Meppelink A" first="Anne Marthe" last="Meppelink">Anne Marthe Meppelink</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F23 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 002F23 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:20960486
|texte= Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:20960486" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |